文献速递妇科

浸润深度≤5mm且水平扩散>7mm的宫颈癌:淋巴结评估是否仅需在LVSI患者中进行?

Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI?
PubMed 文献 · Gynecol Oncol · 2020-05-04

该研究基于荷兰癌症登记数据,纳入170例2009年FIGO IB期、浸润深度≤5mm且水平扩散>7mm的宫颈癌患者,分析淋巴结转移(LNM)发生率及影响因素。结论认为对LVSI阳性或腺癌伴浸润深度3-5mm者应行淋巴结评估,而鳞癌无LVSI、腺癌浸润深度<3mm或任何无LVSI且浸润深度<3mm的肿瘤可省略评估。

要点

  • LVSI阳性宫颈癌患者淋巴结转移率显著更高(9.3% vs 1.7%)。
  • 腺癌伴浸润深度3-5mm者淋巴结转移率达10%。
  • 鳞癌无LVSI、腺癌浸润深度<3mm或无LVSI且浸润深度<3mm者可省略淋巴结评估。

核心结论

  • 对LVSI阳性或腺癌伴浸润深度3-5mm的宫颈癌患者,淋巴结评估是必要的。
  • 对鳞癌无LVSI、腺癌浸润深度<3mm或任何无LVSI且浸润深度<3mm的肿瘤,可省略淋巴结评估。

研究设计与样本

  • 基于荷兰癌症登记数据的回顾性队列研究,纳入2015年1月至2019年5月诊断的170例2009年FIGO IB期、浸润深度≤5mm且水平扩散>7mm的宫颈癌患者。

主要发现

  • 腺癌伴浸润深度3-5mm者淋巴结转移率为10%(4/40)。
  • 鳞癌无LVSI者淋巴结转移率为0/74,腺癌浸润深度<3mm者为0/13,无LVSI且浸润深度<3mm者为0/36。
  • 4年总生存率为98.2%。

关键数值与推荐

  • 淋巴结转移总体发生率3.5%(6/170)。
  • 腺癌伴浸润深度3-5mm者淋巴结转移率10%(4/40)。
  • 鳞癌无LVSI者淋巴结转移率0/74,腺癌浸润深度<3mm者0/13,无LVSI且浸润深度<3mm者0/36。
  • 4年总生存率98.2%。

临床怎么用

  • 对LVSI阳性或腺癌伴浸润深度3-5mm的宫颈癌患者应行盆腔淋巴结评估。
  • 对鳞癌无LVSI、腺癌浸润深度<3mm或任何无LVSI且浸润深度<3mm的肿瘤可考虑省略淋巴结评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread is classified FIGO IA instead of FIGO IB in the revised staging system, as horizontal spread is no longer considered. We aimed to determine the incidence of lymph node metastasis (LNM) and, consequently, the necessity of pelvic lymph node assessment. METHODS: Patients diagnosed between January 2015 and May 2019 with cervical cancer FIGO (2009) stage IB with ≤5 mm depth of invasion and >7 mm horizontal spread, were identified from the Netherlands Cancer Registry. Associations between disease-characteristics and lymph node metastasis (LNM), and overall survival, were assessed. RESULTS: Of 170 patients, six (3.5%) had LNM: 4/53 (7.6%) with adenocarcinoma and 2/117 (1.7%) with squamous cell carcinoma (p = .077). Four-year overall survival was 98.2%. LNM was observed more often in tumours with LVSI (4/43 patients, 9.3%) than without LVSI (2/117 patients, 1.7%) (p = .045). In adenocarcinoma with 3-5 mm depth of invasion LNM rate was 10% (4/40). None of the following tumours were observed with LNM: squamous cell carcinoma without LVSI (0/74); adenocarcinoma with <3 mm depth of invasion (0/13); <3 mm depth of invasion without LVSI (0/36). CONCLUSIONS: Lymph node assessment is essential in any tumour with LVSI or in adenocarcinoma with 3-5 mm depth of invasion. It can be omitted in squamous cell carcinoma without LVSI, in adenocarcinoma with <3 mm depth of invasion and in any tumours without LVSI and with <3 mm depth of invasion.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wenzel HHB, Van Kol KGG, Nijman HW, et al. Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI? Gynecol Oncol. 2020. PMID: 32381363. doi:10.1016/j.ygyno.2020.04.705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。